跳至主要内容
临床试验/NCT06375070
NCT06375070已完成不适用

Anticoagulants for PFO Patients

Xuanwu Hospital, Beijing0 个研究点目标入组 277 人开始时间: 2016年8月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
277
主要终点
whether occur recurrent stroke or migraine relief

研究概览

简要总结

Patients who underwent both bubble transcranial Doppler (bubble-TCD) and transoesophageal echocardiography (TEE) at our institution were consecutively enrolled in this real-world case-control study from August 2016 through August 2023. The patients were categorized into three groups based on the degree of the shunt observed: mild (3-9 bubbles), moderate (10-30bubbles), and severe (more than 30 bubbles). In cases with mild-shunt (small-size) PFO, post-procedural anticoagulation or PFO closure was administered. Subsequent to the interventions, the follow-up encompassed the recording of migraine remission, recurrent neurological incidents, instances of major bleeding, and mortality.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
16 Years 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • verified PFO diagnosis through TEE, Bubble-TCD, or contrast echocardiography of the right heart;
  • ages range between 16 and 65;
  • no restrictions on sexual orientation;
  • stroke patients with cryptogenic strokes as per the TOAST classification;
  • no other likely causes for migraines, with the exception of PFO;
  • no multiple risk factors for cerebrovascular disease, such as hypertension, diabetes, or smoking.

排除标准

  • severe, acute, or life-threatening conditions including acute cardio-cerebrovascular diseases, significant organ failure, or infections; 2)magnetic resonance imaging (MRI) contraindications, especially with contrast enhancement; 3) presence of cerebral artery stenosis, internal carotid artery stenosis, or atherosclerosis; 4) hypercoagulability or venous thrombosis; 5) contraindications associated with PFO closure and anticoagulants; 6) obstructive sleep apnea.

研究组 & 干预措施

small-shunt Group

small (3-9 bubbles)

干预措施: PFO closure (Procedure)

small-shunt Group

small (3-9 bubbles)

干预措施: anticoagulant (Drug)

moderate-shunt Group

(10-30 bubbles)

干预措施: PFO closure (Procedure)

moderate-shunt Group

(10-30 bubbles)

干预措施: anticoagulant (Drug)

large-shunt Group

>30 bubbles

干预措施: PFO closure (Procedure)

large-shunt Group

>30 bubbles

干预措施: anticoagulant (Drug)

结局指标

主要结局

whether occur recurrent stroke or migraine relief

时间窗: 12 months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

相似试验